Skip to Content
Merck
All Photos(1)

Documents

MABN2427

Sigma-Aldrich

Anti-polyQ specific Antibody, clone MW1

clone MW1, from mouse

Synonym(s):

Htt mutant, PolyQ-Htt, Clone MW1, Atrophin-1

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

MW1, monoclonal

species reactivity

mouse, rat, human

packaging

antibody small pack of 25 μg

technique(s)

immunocytochemistry: suitable
immunohistochemistry: suitable
western blot: suitable

isotype

IgG2b

NCBI accession no.

UniProt accession no.

shipped in

ambient

target post-translational modification

unmodified

Gene Information

human ... ATN1(1822)

General description

Huntington disease (HD) is a neurodegenerative disorder caused by an expansion of a polyglutamine (PolyQ) domain in the protein huntingtin (htt) that leads to its aggregation into fibrils. PolyQ expansion above 35 -40 results in disease associated with htt aggregation into inclusion bodies. These expanded PolyQ repeats adopt multiple potentially toxic conformations increase atrophin-1 and huntingtin levels and abnormally sequester proteins that are essential for transcription. PolyQ domains of different lengths can display different conformations. The primary sites of neuropathology show variations between different PolyQ disorders, but usually include the cerebellum, striatum, cerebral cortex, brainstem, spinal cord, and thalamus. Huntington s disease (HD) and dentatorubral pallidoluysian atrophy (DRPLA) display clinical similarities, but exhibit different regional pathologies. For example, in HD striatum is the most affected region whereas in DRPLA dentate nucleus of the cerebellum is more severely affected. Clone MW1 strongly binds to the expanded PolyQ of mutant Htt, but does not display any detectible binding to normal human or wild-type murine Htt. The clone MW1, which bind to the polyQ repeat in htt is reported to increase htt-induced toxicity and aggregation. (The clone MW1, which bind to the polyQ repeat in htt is reported to increased htt-induced toxicity and aggregation. (Ref.: Luthi-Carter, R et al. (2012). Hum. Mol. Gen. 11(17); 1927-1937; Legleiter, J et al. (2009). J. Biol. Chem. 284(32); 21647-21658; Ko, J et al. (2001). Brain Res. Bull. 56 (3/4); 319-329).

Specificity

Clone MW1 specifically recognize the polyQ domain and does not react with wild-type Htt in any significant manner.

Immunogen

GST-tagged recombinant proteins expressed from two constructs containing the polyQ domain (19 repeats) and 34 amino acids of the dentatorubralpalliodoluysian atrophy (DRPLA) gene.

Application

Anti-polyQ specific, clone MW1, Cat. No. MABN2427, is a highly specific mouse monoclonal antibody that targets expanded PolyQ repeats from Huntingtin (Htt) and has been tested for use in Immunocytochemistry, Immunohistochemistry, and Western Blotting.
Research Category
Neuroscience
Western Blotting Analysis: A representative lot detected expanded polyQ repeats in Htt in Western Blotting applications (Ko, J., et. al. (2001). Brain Res Bull. 56(3-4):319-29; Legleiter, J., et. al. (2009). J Biol Chem. 284(32):21647-58).

Immunohistochemistry Analysis: A representative lot detected expanded polyQ repeats in Immunohistochemistry applications (Ko, J., et. al. (2001). Brain Res Bull. 56(3-4):319-29).

Immunocytochemistry Analysis: A representative lot detected expanded polyQ repeats in Immunocytochemistry applications (Legleiter, J., et. al. (2009). J Biol Chem. 284(32):21647-58).

Quality

Evaluated by Western Blotting in mouse brain tissue lysate.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected expanded polyQ repeats in Htt in 10 µg of mouse brain tissue lysate. It does not react with normal Htt.

Target description

~350 kDa observed. Uncharacterized bands may be observed in some lysate(s).

Physical form

Format: Purified
Protein G purified
Purified mouse monoclonal antibody IgG2b in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Other Notes

Concentration: Please refer to lot specific datasheet.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

WGK

WGK 1


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Florian Krach et al.
Nature communications, 13(1), 6797-6797 (2022-11-11)
Huntington's disease (HD) is a neurodegenerative disorder caused by poly-Q expansion in the Huntingtin (HTT) protein. Here, we delineate elevated mutant HTT (mHTT) levels in patient-derived cells including fibroblasts and iPSC derived cortical neurons using mesoscale discovery (MSD) HTT assays.
Anat Bahat et al.
EMBO molecular medicine, 16(3), 523-546 (2024-02-20)
Huntington's disease (HD) is an incurable inherited disorder caused by a repeated expansion of glutamines in the huntingtin gene (Htt). The mutant protein causes neuronal degeneration leading to severe motor and psychological symptoms. Selective downregulation of the mutant Htt gene
Leah Gottlieb et al.
The Journal of biological chemistry, 297(6), 101363-101363 (2021-11-05)
Huntington's disease (HD) is a neurodegenerative disorder caused by a poly-CAG expansion in the first exon of the HTT gene, resulting in an extended poly-glutamine tract in the N-terminal domain of the Huntingtin (Htt) protein product. Proteolytic fragments of the
Jingyun Wu et al.
International journal of molecular sciences, 23(23) (2022-12-12)
Huntington's disease (HD) is a lethal neurodegenerative disorder without efficient therapeutic options. The inefficient translation from preclinical and clinical research into clinical use is mainly attributed to the lack of (i) understanding of disease initiation, progression, and involved molecular mechanisms;
Kathryn H Morelli et al.
Nature neuroscience, 26(1), 27-38 (2022-12-13)
Huntington's disease (HD) is a fatal, dominantly inherited neurodegenerative disorder caused by CAG trinucleotide expansion in exon 1 of the huntingtin (HTT) gene. Since the reduction of pathogenic mutant HTT messenger RNA is therapeutic, we developed a mutant allele-sensitive CAGEX

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service